These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

175 related items for PubMed ID: 31041833

  • 1. Rapid characterization of structural and functional similarity for a candidate bevacizumab (Avastin) biosimilar using a multipronged mass-spectrometry-based approach.
    Brown KA, Rajendran S, Dowd J, Wilson DJ.
    Drug Test Anal; 2019 Aug; 11(8):1207-1217. PubMed ID: 31041833
    [Abstract] [Full Text] [Related]

  • 2. Epitope Mapping for a Preclinical Bevacizumab (Avastin) Biosimilar on an Extended Construct of Vascular Endothelial Growth Factor A Using Millisecond Hydrogen-Deuterium Exchange Mass Spectrometry.
    Brown KA, Lento C, Rajendran S, Dowd J, Wilson DJ.
    Biochemistry; 2020 Aug 04; 59(30):2776-2781. PubMed ID: 32672953
    [Abstract] [Full Text] [Related]

  • 3. LC-MS based case-by-case analysis of the impact of acidic and basic charge variants of bevacizumab on stability and biological activity.
    Singh SK, Kumar D, Malani H, Rathore AS.
    Sci Rep; 2021 Jan 29; 11(1):2487. PubMed ID: 33514790
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Comparative higher-order structure analysis of antibody biosimilars using combined bottom-up and top-down hydrogen-deuterium exchange mass spectrometry.
    Pan J, Zhang S, Borchers CH.
    Biochim Biophys Acta; 2016 Dec 29; 1864(12):1801-1808. PubMed ID: 27569733
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Nonclinical assessments of the potential biosimilar PF-06439535 and bevacizumab.
    Peraza MA, Rule KE, Shiue MHI, Finch GL, Thibault S, Brown PR, Clarke DW, Leach MW.
    Regul Toxicol Pharmacol; 2018 Jun 29; 95():236-243. PubMed ID: 29574193
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Analytical and functional similarity of Amgen biosimilar ABP 215 to bevacizumab.
    Seo N, Polozova A, Zhang M, Yates Z, Cao S, Li H, Kuhns S, Maher G, McBride HJ, Liu J.
    MAbs; 2018 Jun 29; 10(4):678-691. PubMed ID: 29553864
    [Abstract] [Full Text] [Related]

  • 10. Recent advances in structural mass spectrometry methods in the context of biosimilarity assessment: from sequence heterogeneities to higher order structures.
    Castel J, Delaux S, Hernandez-Alba O, Cianférani S.
    J Pharm Biomed Anal; 2023 Nov 30; 236():115696. PubMed ID: 37713983
    [Abstract] [Full Text] [Related]

  • 11. Analytical Similarity of a Proposed Biosimilar BVZ-BC to Bevacizumab.
    Yu C, Zhang F, Xu G, Wu G, Wang W, Liu C, Fu Z, Li M, Guo S, Yu X, Wang L.
    Anal Chem; 2020 Feb 18; 92(4):3161-3170. PubMed ID: 31983199
    [Abstract] [Full Text] [Related]

  • 12. Similarity demonstrated between isolated charge variants of MB02, a biosimilar of bevacizumab, and Avastin® following extended physicochemical and functional characterization.
    Ruppen I, Beydon ME, Solís C, Sacristán D, Vandenheede I, Ortiz A, Sandra K, Adhikary L.
    Biologicals; 2021 Sep 18; 73():41-56. PubMed ID: 34593306
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. A Modified Traveling Wave Ion Mobility Mass Spectrometer as a Versatile Platform for Gas-Phase Ion-Molecule Reactions.
    Czar MF, Marchand A, Zenobi R.
    Anal Chem; 2019 May 21; 91(10):6624-6631. PubMed ID: 31008583
    [Abstract] [Full Text] [Related]

  • 15. Achieving multiple hydrogen/deuterium exchange timepoints of carbohydrate hydroxyls using theta-electrospray emitters.
    Kim HJ, Gallagher ES.
    Analyst; 2020 Apr 14; 145(8):3056-3063. PubMed ID: 32141454
    [Abstract] [Full Text] [Related]

  • 16. Assessment of biosimilarity under native and heat-stressed conditions: rituximab, bevacizumab, and trastuzumab originators and biosimilars.
    Kang J, Halseth T, Vallejo D, Najafabadi ZI, Sen KI, Ford M, Ruotolo BT, Schwendeman A.
    Anal Bioanal Chem; 2020 Jan 14; 412(3):763-775. PubMed ID: 31853605
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Cutting-edge mass spectrometry characterization of originator, biosimilar and biobetter antibodies.
    Beck A, Debaene F, Diemer H, Wagner-Rousset E, Colas O, Van Dorsselaer A, Cianférani S.
    J Mass Spectrom; 2015 Feb 14; 50(2):285-97. PubMed ID: 25800010
    [Abstract] [Full Text] [Related]

  • 19. Multifaceted assessment of rituximab biosimilarity: The impact of glycan microheterogeneity on Fc function.
    Kang J, Kim SY, Vallejo D, Hageman TS, White DR, Benet A, Coghlan J, Sen KI, Ford M, Saveliev S, Tolbert TJ, Weis DD, Schwendeman SP, Ruotolo BT, Schwendeman A.
    Eur J Pharm Biopharm; 2020 Jan 14; 146():111-124. PubMed ID: 31841688
    [Abstract] [Full Text] [Related]

  • 20. Production of monoclonal antibodies for measuring Avastin and its biosimilar by Sandwich ELISA.
    Li M, An W, Wang L, Zhang F, Li J, Zhang Y, Li Y, Li H, Ren W, Zhao R, Xia C, Sun L.
    J Immunol Methods; 2019 Jun 14; 469():42-46. PubMed ID: 30943379
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.